PTO/SB/68 (09-06)

Approved for use through 3/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14	
RECEIVED In re Application of Bring completed form to:	
File Information Unit. Room 2E04 2900 Crystal Oriva 0 2008 Arington, VA 22202-3514 Application Number OSI 026, 957	Filed Mar, 5 1993
Telephone restionation	Paper No. 3 7
I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):	
United States Patent Application Publication No page,	
United States Patent Number 5654402 column, fine,	or
WIPO Pub. No, page, line	·
Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site (www.uspto.gov). Terminals that allow access to Public PAIR are available in the Public Search Room. The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)). For published applications that are still pending, a member of the public may obtain a copy of: the file contents; the pending application as originally filed; or any document in the file of the pending application. For unpublished applications that are still pending: (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application in accordance with PCT Article 21(2), a member of the public may obtain a copy of the file contents; the pending application as originally filed; or any document in the file of the pending application. (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of the pending application as originally filed.	
SHAHAB GHAYON	RECEIVED FORBYOUSEBURY
Typed or printed name	-
Registration Number, if applicable	Heunformation Unit
7071 555-0000 Unit_	
Telephone Number	

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.





United States Patent [19]

Boyle et al.

[11] Patent Number: 5,654,407

Date of Patent: [45]

Aug. 5, 1997

[54] HUMAN ANTI-TNF ANTIBODIES

[75] Inventors: Petra Boyle, Pinole; Gayle D. Wetzel,

Martinez; Kenneth J. Lembach,

Danville, all of Calif.

[73] Assignee: Bayer Corporation, Berkeley, Calif.

[21] Appl. No.: 435,246

[22] Filed: May 5, 1995

Related U.S. Application Data

[63] Continuation of Ser. No. 145,060, Oct. 29, 1993, abandoned, which is a continuation-in-part of Ser. No. 26,957, Mar. 5,

[51] Int. Cl.⁶ C07K 16/24

530/388.15; 424/142.1; 424/145.1; 424/158.1; 435/335; 530/388.23;

530/388.24

[58] Field of Search 424/142.1, 145.1, 424/158.1; 435/70.21, 172.2, 335; 530/388.15, 388.23, 388.24, 389.2

[56]

References Cited **PUBLICATIONS**

Rhein, R., "Another Sepsis Drug Down—Immunex' TNF Receptor," Biotechnology Newswatch Oct. 4, 1993,

McGraw Hill, Publishers., pp. 2-3.

Boyle et al., "A Novel Monoclonal Human IgM Autoantibody Which Binds Recombinant Human and Mouse Tumor Necrosis Factor-α," Cell. Immunol. 152:556-568, 1993.

Boyle et al., "The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNFa on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope," Cell. Immunol. 152:569-581, 1993.

Primary Examiner-Robert D. Budens

Attorney, Agent, or Firm-James A. Giblin

ABSTRACT

Human monoclonal antibodies (mAbs) which bind to human TNFa are disclosed. Autoantibodies of both the IgM and IgG isotypes are disclosed. A preferred human monoclonal antibody is known as B5 (F78-1A10-B5 mAb) and it binds to recombinant human TNFα (rhTNFα) in ELISA format with a titer comparable to three high affinity neutralizing mouse mAbs. It also binds to cell surface TNFa and prevents TNFa secretion by human monocyte cell lines.

12 Claims, 11 Drawing Sheets